Previous studies reported default mode network (DMN) and limbic network (LIN) brain perfusion deficits in patients with amnestic mild cognitive impairment (aMCI), frequently a prodromal stage of Alzheimer’s disease (AD). However, the validity of these measures as AD markers has not yet been tested using MRI arterial spin labeling (ASL).
Objective:
To investigate the convergent and discriminant validity of DMN and LIN perfusion in aMCI.
Methods:
We collected core AD markers (amyloid-β 42 [Aβ42], phosphorylated tau 181 levels in cerebrospinal fluid [CSF]), neurodegenerative (hippocampal volumes and CSF total tau), vascular (white matter hyperintensities), genetic (apolipoprotein E [APOE] status), and cognitive features (memory functioning on Paired Associate Learning test [PAL]) in 14 aMCI patients. Cerebral blood flow (CBF) was extracted from DMN and LIN using ASL and correlated with AD features to assess convergent validity. Discriminant validity was assessed carrying out the same analysis with AD-unrelated features, i.e., somatomotor and visual networks’ perfusion, cerebellar volume, and processing speed.
Results:
Perfusion was reduced in the DMN (F = 5.486, p = 0.039) and LIN (F = 12.678, p = 0.004) in APOE ɛ4 carriers compared to non-carriers. LIN perfusion correlated with CSF Aβ42 levels (r = 0.678, p = 0.022) and memory impairment (PAL, number of errors, r = –0.779, p = 0.002). No significant correlation was detected with tau, neurodegeneration, and vascular features, nor with AD-unrelated features.
Conclusion:
Our results support the validity of DMN and LIN ASL perfusion as AD markers in aMCI, indicating a significant correlation between CBF and amyloidosis, APOE ɛ4, and memory impairment.
PetersenRC (2009) Early diagnosis of Alzheimer’s disease: Is MCI too late?Curr Alzheimer Res6, 324–30.
2.
PrestiaA, CaroliA, van der FlierWM, OssenkoppeleR, Van BerckelB, BarkhofF, TeunissenCE, WallAE, CarterSF, SchollM, ChooIH, NordbergA, ScheltensP, FrisoniGB (2013) Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology80, 1048–1056.
3.
MattssonN, ZetterbergH, HanssonO, AndreasenN, ParnettiL, JonssonM, HerukkaS, van der FlierWM, BlankensteinMA, EwersM, RichK, KaiserE, VerbeekM, TsolakiM, MulugetaE, RosénE, AarslandD, VisserPJ, SchröderJ, MarcussonJ, de LeonM, HampelH, ScheltensP, PirttiläT, WallinA, JönhagenME, MinthonL, WinbladB, BlennowK (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385–393.
4.
JackCRJr, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
5.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
6.
KislerK, NelsonAR, MontagneA, ZlokovicBV (2017) Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci18, 419–434.
7.
JezzardP, ChappellMA, OkellTW (2018) Arterial spin labeling for the measurement of cerebral perfusion and angiography. J Cereb Blood Flow Metab38, 603–626.
8.
WilliamsDS, DetreJA, LeighJS, KoretskyAP (1992) Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Natl Acad Sci U S A89, 212–216.
9.
ZhangN, GordonML, GoldbergTE (2017) Cerebral blood flow measured by arterial spin labeling MRI at resting state in normal aging and Alzheimer’s disease. Neurosci Biobehav Rev72, 168–175.
10.
BangenKJ, RestomK, LiuTT, WierengaCE, JakAJ, SalmonDP, BondiMW (2012) Assessment of Alzheimer’s disease risk with functional magnetic resonance imaging: An arterial spin labeling study. J Alzheimers Dis31, S59–S74.
11.
LouW, ShiL, WongA, ChuWC, MokVC, WangD (2016) Changes of cerebral perfusion and functional brain network organization in patients with mild cognitive impairment. J Alzheimers Dis54, 397–409.
12.
JohnsonNA, JahngG, WeinerMW, MillerBL, ChuiHC, JagustWJ, Gorno-TempiniML, SchuffN (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial experience. Radiology234, 851–859.
13.
AlexopoulosP, SorgC, FörschlerA, GrimmerT, SkokouM, WohlschlägerA, PerneczkyR, ZimmerC, KurzA, PreibischC (2012) Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer’s disease measured by pulsed arterial spin labeling MRI. Eur Arch Psychiatry Clin Neurosci262, 69–77.
14.
OkonkwoOC, XuG, OhJM, DowlingNM, CarlssonCM, GallagherCL, BirdsillAC, PalottiM, WhartonW, HermannBP, LaRueA, BendlinBB, RowleyHA, AsthanaS, SagerMA, JohnsonSC (2014) Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer’s disease. Cereb Cortex24, 978–988.
KimC, AlvaradoRL, StephensK, WeyH, WangDJJ, LeritzEC, SalatDH (2020) Associations between cerebral blood flow and structural and functional brain imaging measures in individuals with neuropsychologically defined mild cognitive impairment. Neurobiol Aging86, 64–74.
17.
PievaniM, FilippiniN, Van Den Heuvel, MartijnP, CappaSF, FrisoniGB (2014) Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy. Nat Revs Neurol10, 620–633.
18.
BadhwarA, TamA, DansereauC, OrbanP, HoffstaedterF, BellecP (2017) Resting-state network dysfunction in Alzheimer’s disease: A systematic review and meta-analysis. Alzheimers Dement (Amst)8, 73–85.
19.
PiniL, GeroldiC, GalluzziS, BaruzziR, BertocchiM, ChitòE, OriniS, RomanoM, CotelliM, RosiniS, MagnaldiS, MorassiM, CobelliM, BonviciniC, ArchettiS, ZanettiO, FrisoniGB, PievaniM (2020) Age at onset reveals different functional connectivity abnormalities in prodromal Alzheimer’s disease. Brain Imaging Behav14, 2594–2605.
20.
De VogelaereF, SantensP, AchtenE, BoonP, VingerhoetsG (2012) Altered default-mode network activation in mild cognitive impairment compared with healthy aging. Neuroradiology54, 1195–1206.
21.
LeeE, YooK, LeeY, ChungJ, LimJ, YoonB, JeongY (2016) Default mode network functional connectivity in early and late mild cognitive impairment. Alzheimer Dis Assoc Disord30, 289–296.
22.
GourN, FelicianO, DidicM, KoricL, GueriotC, ChanoineV, Confort-GounyS, GuyeM, CeccaldiM, RanjevaJP (2014) Functional connectivity changes differ in early and late-onset alzheimer’s disease. Hum Brain Mapp35, 2978–2994.
23.
MaassA, BerronD, HarrisonTM, AdamsJN, La JoieR, BakerS, MellingerT, BellRK, SwinnertonK, InglisB, RabinoviciGD, DüzelE, JagustWJ (2019) Alzheimer’s pathology targets distinct memory networks in the ageing brain. Brain142, 2492–2509.
24.
BraakH, BraakE (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging18, 351–357.
25.
PalmqvistS, SchöllM, StrandbergO, MattssonN, StomrudE, ZetterbergH, BlennowK, LandauS, JagustW, HanssonO (2017) Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun8, 1–13.
26.
ChoH, LeeHS, ChoiJY, LeeJH, RyuYH, LeeMS, LyooCH (2018) Predicted sequence of cortical tau and amyloid-β deposition in Alzheimer disease spectrum. Neurobiol Aging68, 76–84.
27.
RanganathC, RitcheyM (2012) Two cortical systems for memory-guided behaviour. Nat Rev Neurosci13, 713–726.
28.
CataniM, Dell’AcquaF, De SchottenMT (2013) A revised limbic system model for memory, emotion and behaviour. Neurosci Biobehav Rev37, 1724–1737.
29.
BarbeauE, DidicM, TramoniE, FelicianO, JoubertS, SontheimerA, CeccaldiM, PoncetM (2004) Evaluation of visual recognition memory in MCI patients. Neurology62, 1317–1322.
30.
TosunD, SchuffN, RabinoviciGD, AyaktaN, MillerBL, JagustW, KramerJ, WeinerMM, RosenHJ (2016) Diagnostic utility of ASL-MRI and FDG-PET in the behavioral variant of FTD and AD. Ann Clinical Transl Neurol3, 740–751.
31.
HaysCC, ZlatarZZ, WierengaCE (2016) The utility of cerebral blood flow as a biomarker of preclinical Alzheimer’s disease. Cell Mol Neurobiol36, 167–179.
32.
BinnewijzendMA, KuijerJP, BenedictusMR, van der Flier, WiesjeM, WinkAM, WattjesMP, van BerckelBN, ScheltensP, BarkhofF (2013) Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: A marker for disease severity. Radiology267, 221–230.
33.
ChaoLL, BuckleyST, KornakJ, SchuffN, MadisonC, YaffeK, MillerBL, KramerJH, WeinerMW (2010) ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis Assoc Disord24, 19–27.
34.
MattssonN, TosunD, InselPS, SimonsonA, JackCRJr, BeckettLA, DonohueM, JagustW, SchuffN, WeinerMW (2014) Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer’s disease and mild cognitive impairment. Brain137, 1550–1561.
35.
KikukawaT, AbeT, AtakaS, SaitoH, HasegawaI, MinoT, TakeuchiJ, KawabeJ, WadaY, WatanabeY, ItohY (2018) Amyloid deposition and CBF patterns predict conversion of mild cognitive impairment to dementia. Neurol Sci39, 1597–1602.
36.
TosunD, SchuffN, JagustW, WeinerMW, Alzheimer’s Disease Neuroimaging Initiative (2016) Discriminative power of arterial spin labeling magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography changes for amyloid-beta-positive subjects in the Alzheimer’s disease continuum. Neurodegener Dis16, 87–94.
37.
HabertM, de SouzaLC, LamariF, DaragonN, DesarnaudS, JardelC, DuboisB, SarazinM (2010) Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease. Eur J Nucl Med Mol Imaging37, 589–593.
38.
LeuzyA, Rodriguez-VieitezE, Saint-AubertL, ChiotisK, AlmkvistO, SavitchevaI, JonassonM, LubberinkM, WallA, AntoniG, NordbergA (2018) Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer’s disease. Alzheimers Dement14, 652–663.
39.
CaroliA, TestaC, GeroldiC, NobiliF, GuerraUP, BonettiM, FrisoniGB (2007) Brain perfusion correlates of medial temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment. J Neurol254, 1000–1008.
40.
De VisJB, PengS, ChenX, LiY, LiuP, SurS, RodrigueKM, ParkDC, LuH (2018) Arterial-spin-labeling (ASL) perfusion MRI predicts cognitive function in elderly individuals: A 4-year longitudinal study. J Magn Reson Imaging48, 449–458.
41.
WierengaCE, DevSI, ShinDD, ClarkLR, BangenKJ, JakAJ, RissmanRA, LiuTT, SalmonDP, BondiMW (2012) Effect of mild cognitive impairment and APOE genotype on resting cerebral blood flow and its association with cognition. J Cerebl Blood Flow Metab32, 1589–1599.
42.
KimSM, KimMJ, RheeHY, RyuC, KimEJ, PetersenET, JahngG (2013) Regional cerebral perfusion in patients with Alzheimer’s disease and mild cognitive impairment: Effect of APOE epsilon4 allele. Neuroradiology55, 25–34.
GrotheMJ, TeipelSJ, Alzheimer’s Disease Neuroimaging Initiative (2016) Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer’s disease correspond to dissociable functional brain networks. Hum Brain Mapp37, 35–53.
45.
FirthNC, PrimativoS, BrotherhoodE, YoungAL, YongKX, CrutchSJ, AlexanderDC, OxtobyNP (2020) Sequences of cognitive decline in typical Alzheimer’s disease and posterior cortical atrophy estimated using a novel event-based model of disease progression. Alzheimers Dement16, 965–973.
46.
GalluzziS, MarizzoniM, BabiloniC, AlbaniD, AntelmiL, BagnoliC, Bartres-FazD, CordoneS, DidicM, FarottiL, FiedlerU, ForloniG, GirtlerN, HenschT, JovicichJ, LeeuwisA, MarraC, MolinuevoJL, NobiliF, ParienteJ, ParnettiL, PayouxP, Del PercioC, RanjevaJP, RolandiE, RossiniPM, SchönknechtP, SoricelliA, TsolakiM, VisserPJ, WiltfangJ, RichardsonJC, BordetR, BlinO, FrisoniGB (2016) Clinical and biomarker profiling of prodromal Alzheimer’s disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: A ‘European ADNI study’. J Intern Med279, 576–591.
BuxtonRB, FrankLR, WongEC, SiewertB, WarachS, EdelmanRR (1998) A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med40, 383–396.
49.
AlsopDC, DetreJA, GolayX, GüntherM, HendrikseJ, Hernandez-GarciaL, LuH, MacIntoshBJ, ParkesLM, SmitsM, van OschMJP, WangDJJ, WongEC, ZaharchukG (2015) Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med73, 102–116.
50.
DuAT, JahngGH, HayasakaS, KramerJH, RosenHJ, Gorno-TempiniML, RankinKP, MillerBL, WeinerMW, SchuffN (2006) Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology67, 1215–1220.
51.
SchaeferA, KongR, GordonEM, LaumannTO, ZuoX, HolmesAJ, EickhoffSB, YeoBT (2018) Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI. Cereb Cortex28, 3095–3114.
52.
BackhausenLL, HertingMM, BuseJ, RoessnerV, SmolkaMN, VetterNC (2016) Quality control of structural MRI images applied using FreeSurfer—a hands-on workflow to rate motion artifacts. Front Neurosci10, 558.
53.
DaleAM, FischlB, SerenoMI (1999) Cortical surface-based analysis: I. Segmentation and surface reconstruction. Neuroimage9, 179–194.
54.
FischlB, SerenoMI, DaleAM (1999) Cortical surface-based analysis: II: inflation, flattening, and a surface-based coordinate system. Neuroimage9, 195–207.
55.
FischlB, SalatDH, BusaE, AlbertM, DieterichM, HaselgroveC, Van Der KouweA, KillianyR, KennedyD, KlavenessS, MontilloA, MakrisN, RosenB, DaleAM (2002) Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron33, 341–355.
56.
SchmidtP, GaserC, ArsicM, BuckD, FörschlerA, BertheleA, HoshiM, IlgR, SchmidVJ, ZimmerC, HemmerB, MühlauM (2012) An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage59, 3774–3783.
HallidayMR, RegeSV, MaQ, ZhaoZ, MillerCA, WinklerEA, ZlokovicBV (2016) Accelerated pericyte degeneration and blood–brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. J Cereb Blood Flow Metab36, 216–227.
64.
LiuC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–108.
65.
WebbCE, FosterCM, HornMM, KennedyKM, RodrigueKM (2020) Beta-amyloid burden predicts poorer mnemonic discrimination in cognitively normal older adults. Neuroimage221, 117199.
66.
TostoG, ZimmermanME, HamiltonJL, CarmichaelOT, BrickmanAM, Alzheimer’s Disease Neuroimaging Initiative (2015) The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. Alzheimers Dement11, 1510–1519.
67.
McAleeseKE, FirbankM, DeyM, CollobySJ, WalkerL, JohnsonM, BeverleyJR, TaylorJP, ThomasAJ, O’BrienJT, AttemsJ (2015) Cortical tau load is associated with white matter hyperintensities. Acta Neuropathol Commun3, 1–11.
68.
PereiraJB, OssenkoppeleR, PalmqvistS, StrandbergTO, SmithR, WestmanE, HanssonO (2019) Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. Elife8, e50830.
69.
VogelJW, Iturria-MedinaY, StrandbergOT, SmithR, LevitisE, EvansAC, HanssonO (2020) Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease. Nat Commun11, 2612.
